Note: The label's adverse event data come from ATTR-CM trials of VYNDAQEL (tafamidis meglumine), as the first passage states. The second passage is from the FDA-approved Patient Information printed with the label.
Vyndamax ATTR-ACT trial: how often did Vyndaqel patients stop for side effects?
Note: These passages describe a post hoc, interim analysis of the ATTR-ACT long-term extension, in which patients received VYNDAQEL and then transitioned to VYNDAMAX.
Note: The dosing page of the Vyndamax HCP site cites the 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis for this statement.